IL2 and neoplasm: To evaluate the therapeutic potential of receptor‐biased PEGylated IL‐2 variants, we established a syngeneic B16F10 melanoma model by subcutaneously inoculating 1 × 10^5 tumor cells into the right flank of female C57BL/6 mice.